Heart Disease Risk Determines Menopausal Age Rather Than the Reverse
Helen S. Kok,Kristel M. van Asselt,Kristel M. van Asselt,Yvonne T. van der Schouw,Ingeborg van der Tweel,Petra H.M. Peeters,Peter W.F. Wilson,Peter L. Pearson,Diederick E. Grobbee +8 more
TLDR
The findings support the view that heart disease risk determines age at menopause and offers a novel explanation for the inconsistent findings on cardiovascular disease rate and its relationship to menopausal age and effects of hormone replacement therapy.About:
This article is published in Journal of the American College of Cardiology.The article was published on 2006-05-16 and is currently open access. It has received 214 citations till now. The article focuses on the topics: Framingham Risk Score & Framingham Heart Study.read more
Citations
More filters
Journal ArticleDOI
Ovarian Aging: Mechanisms and Clinical Consequences
TL;DR: Improved knowledge of the ovarian ageing mechanisms may ultimately provide tools for prediction of menopause and manipulation of the early steps of folliculogenesis for the purpose of contraception and fertility lifespan extension.
Journal ArticleDOI
The 2017 hormone therapy position statement of The North American Menopause Society.
JoAnn V. Pinkerton,Fernando Sánchez Aguirre,Jennifer Blake,Felicia Cosman,Howard N. Hodis,Susan Hoffstetter,Andrew M. Kaunitz,Sheryl A. Kingsberg,Pauline M. Maki,JoAnn E. Manson,Polly Marchbanks,Michael R. McClung,Lila E. Nachtigall,Lawrence M. Nelson,Diane Todd Pace,Robert L. Reid,Phillip M. Sarrel,Jan L. Shifren,Cynthia A. Stuenkel,Wulf H. Utian +19 more
TL;DR: Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause (GSM) and has been shown to prevent bone loss and fracture.
Journal ArticleDOI
The 2012 hormone therapy position statement of the North American Menopause Society
TL;DR: The more favorable benefit-risk ratio for ET allows more flexibility in extending the duration of use compared with EPT, where the earlier appearance of increased breast cancer risk precludes a recommendation for use beyond 3 to 5 years.
Journal ArticleDOI
Are Changes in Cardiovascular Disease Risk Factors in Midlife Women due to Chronological Aging or to the Menopausal Transition
Karen A. Matthews,Sybil L. Crawford,Claudia U. Chae,Susan A. Everson-Rose,MaryFran Sowers,Barbara Sternfeld,Kim Sutton-Tyrrell +6 more
TL;DR: Only total cholesterol, low-density lipoprotein cholesterol, and apolipoprotein B demonstrated substantial increases within the 1-year interval before and after the FMP, consistent with menopause-induced changes.
Journal ArticleDOI
Menopause and the metabolic syndrome: the Study of Women's Health Across the Nation
TL;DR: As testosterone progressively dominates the hormonal milieu during the menopausal transition, the prevalence of MetS increases, independent of aging and other important covariates, which may be a pathway by which cardiovascular disease increases during menopause.
References
More filters
Journal ArticleDOI
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Scott M. Grundy,David W. Bilheimer,Alan Chait,Luther T. Clark,Margo A. Denke,Richard J. Havel,William R. Hazzard,Stephen B. Hulley,Donald B. Hunninghake,Robert A. Kreisberg,Penny M. Kris-Etherton,James M. McKenney,Michael A. Newman,Ernst J. Schaefer,Burton E. Sobel,Carolyn Somelofski,Milton C. Weinstein,H. Bryan Brewer,James I. Cleeman,Karen A. Donato,Nancy D. Ernst,Jeffrey M. Hoeg,Basil M. Rifkind,Jacques E. Rossouw,Christopher T. Sempos,Joanne M. Gallivan,Maureen N. Harris,Laurie Quint-Adler +27 more
TL;DR: Dairy therapy remains the first line of treatment of high blood cholesterol, and drug therapy is reserved for patients who are considered to be at high risk for CHD, and the fundamental approach to treatment is comparable.
Journal ArticleDOI
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
Jacques E. Rossouw,Garnet L. Anderson,Ross L. Prentice,Andrea Z. LaCroix,Charles Kooperberg,Marcia L. Stefanick,Rebecca D. Jackson,Shirley A.A. Beresford,Barbara V. Howard,Karen C. Johnson,Jane Morley Kotchen,Judith K. Ockene +11 more
TL;DR: Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.
Journal ArticleDOI
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
Jaakko Tuomilehto,Jon Lindstrom,Johan G. Eriksson,Valle Tt,Helena Hämäläinen,Pirjo Ilanne-Parikka,Keinänen-Kiukaanniemi S,Mauri Laakso,Anne Louheranta,Rastas M,Salminen,Matti Uusitupa +11 more
TL;DR: Type 2 diabetes can be prevented by changes in the lifestyles of high-risk subjects by means of individualized counseling aimed at reducing weight, total intake of fat, and intake of saturated fat and increasing intake of fiber and physical activity.
Journal ArticleDOI
Prediction of Coronary Heart Disease Using Risk Factor Categories
Peter W.F. Wilson,Ralph B. D'Agostino,Daniel Levy,Albert M. Belanger,Halit Silbershatz,William B. Kannel +5 more
TL;DR: A simple coronary disease prediction algorithm was developed using categorical variables, which allows physicians to predict multivariate CHD risk in patients without overt CHD.
Journal ArticleDOI
Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
Stephen B. Hulley,Deborah Grady,Trudy L. Bush,Curt D Furberg,David M. Herrington,Betty Riggs,Eric Vittinghoff +6 more
TL;DR: Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease and the treatment did increase the rate of thromboembolic events and gallbladder disease.